It’s all about your risk tolerance, I am just stating mine, not dictating what yours should be.
1 Like
Sure, it looks interesting, but its going to be 5 to 10 years before its FDA approved and available commercially, if it ever makes it through the phase 3 trials.
4 Likes
This is far from true. Because of the much longer plasma half-life of rapamycin and over 7 times slower metabolism of humans compared to mice, daily intake in mice is actually pretty close to a weekly intake for humans. In addition, you need to apply metabolic scaling to estimate the human equivalent doses.
2 Likes
This isn’t an accurate statement, so I’m guessing you meant that they share certain subunits.
One can regulate the other as they’re part of the same cellular network, but they are assembled independently and one is not necessary for the other’s formation.
I think what Joseph is trying to say is that there is a poorly defined feedback mechanism whereby if you inhibit mTORC1 at a high level, consistently over a longer period of time, you eventually see mTORC2 inhibition. I’ve yet to see any researchers define this process in any detail, and the exact dosing level needed, and the days of dosing required, are not well defined and likely vary by person.
So, it’s a general concept right now. If you inhibit mTORC1 long enough at a high enough level, you will eventually get mTORC2 inhibition with rapamycin. Beyond that I don’t think we know a ton, in this area. (IMHO).
5 Likes
I partially agree with you but the through levels aren’t just a function of the frequency of dosing but of the dose. If humans were to take massive doses like the mice in the rodent studies, then they would have significant through levels even if they take it just once a week. The mice given rapamycin daily are getting a dose of rapamycin every 1.6 half-lives (with their 15 hour plasma half-life). For a human with a 60 hour half life,1.6 half-lives would be 96 hours or 4 days. So if we go by half-lives, a dose given to a mouse daily is equivalent to a dose given every 4 days for a human. If we compare metabolic rates a dose given daily to a mouse would be somewhat similar to once weekly for a human given that humans have roughly 7-times slower metabolic rates. Given this, a daily dose for a mouse would be close to a dose given 1-2 times weekly for a human, depending on whether we use the half-life or metabolic rate to translate the doses. Since most people are taking it weekly, one could argue that the mice are getting it a bit more frequently but the difference isn’t huge. That said, the mice are certainly getting more constant exposures because they don’t generally reach close to zero through levels between doses, but that’s largely because they are given such large doses relative to what humans are getting. If an adult human were to take 10 mg twice weekly or 20 mg weekly they too would have through levels fairly close to that of the mice.
1 Like
According to Alan green from his website:
Mice daily dosing is 3.75 half lives
Humans have a half life of 62 hours
Now to match that mice 3.75 half-life, it would be about 10 days for humans
Once a week gives humans 2.75 half lives. So mice go through more half lives in a day than humans in a week.
1 Like
Argue this with David Sabatini.
As that is the person who has stated this many times.
You’re missing the core point. The mice and marmosets on life-extending doses never see plasma levels lower than the levels seen in transplant patients under daily dosing. People taking once-weekly doses get lower than that at least as fast, if not faster, than 24 hours after their weekly dose because they fully run out terminal half-life and spend much of the week at far lower levels instead of taking a new dose and reaching a steady-state trough level.
1 Like
You make a valid point. Most of the lifespan studies use doses that are so high that they won’t reach a low through between the doses. There is still some evidence that such a high frequency that doesn’t allow for a low through level between doses isn’t necessary to get at least some of the lifespan benefits. A lower frequency will probably give a lot of benefits also. Note that rapamycin given to old mice every 5 days (at a dose of 2 mg/kg intraperitoneally) also appears to increase lifespan, although more studies are needed testing such lower frequency. Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice - PubMed Importantly, that is a regimen that result in a low through level between doses. Their level is just under 5 ng/mL on day 3 after rapamycin dosing as seen by Figure 1 in PMID: 26463117. That should be enough to reach a low through on day 4-5.
2 Likes
Exactly. That’s my understanding too from the studies I’ve read that discuss how rapamycin inhibits mTORC2. That’s also why I think the search for some better mTOR inhibitor than rapamycin is largely futile, given that rapamycin is already a very “clean” mTORC1 inhibitor.
2 Likes
You may be entirely right… perhaps all mTORC1 inhibitors eventually inhibit mTORC2. It remains to be seen.
But it is interesting that Joan Mannick suggests that even with ongoing and very high dosing of their new mTOR1 inhibitor they don’t seem to see the lipid and glucose disregulation that is typically attributed to mTORC2 inhibition… I can’t wait to see more data on these compounds from Tornado therapeutics.
6 Likes
That’s very interesting! If true, I wonder what causes that. Maybe the new inhibitor has different absorption in differnt tissues relative to rapamycin. One area that could be improved is tissue specifity. Maybe some new inhibitor is able to more easily cross the blood-brain-barrier or tends to accumulate less in whatever bodily compartments that result in the lipid and glucose dysregulation
2 Likes
The wormbot data seems to suggest glucose issues are specific to Rapa. Berberine boosts the effectiveness of Rapa, but not any of the more effective mtor inhibitors (and seems to be a major negative with them).
2 Likes
Since mtor is present in both mtorc1 and mtorc2 complexes I think one would have to inhibit a downstream effector of the mtorc1 pathway to create an inhibitor that didn’t affect mtorc2.
1 Like
I’m not aware of that data. Can you post a link to it?
I agree with that.
2 Likes
Sure. You are going to want to check both multiple and single interventions. https://orabiomedical.com/mmcleaderboard/
That result has never been replicated, and there are important caveats to it, as noted here.
This is a glass mostly full, not a glass partly empty. Three days after dosing, they still have plasma levels similar to transplant patients, and higher than humans 24 hours after taking a once-weekly 5 mg dose.
Yes and that’s a shame. I think it’s very important to do more studies on this kind of intermittent regimens that minimize side effects and translate into more realistic regimens for humans to follow. I think the ITP should do studies on rapamycin given every 3 or 5 days or so in mice.
Yes, but despite that, the dose was still low enough to not result in significant impairment in glucose tolerance. That is a strong sign that it inhibited mTORC1 a lot while not resulting in a major inhibition of mTORC2. A somewhat equivalent regimen for humans in this respect would be to take a high dose of rapamycin at a very low frequency that does not influence glucose levels significantly, and then reduce the frequency of rapamycin dosing gradually just up to the point at which glucose tolerance starts getting worse. That point would be similar in that it would cause the most mTORC1 inhibition you can get without significant mTORC2 inhibition, which I think is a reasonable goal IMO.
1 Like